Citations

Clear

1526 citation(s) found for "Sun, C".

Tissue interactions, cell signaling and transcriptional control in the cranial mesoderm during craniofacial development
Fan, Xiaochen , Loebel, David A.F., Bildsoe, Heidi , Wilkie, Emilie , Wang, Junwen , Qin, Jing , Tam, Patrick , Wang, Junwen

Mayo Clinic

AIMS Genetics | April 12, 2016 | Volume: 03 | Issue: 01 | Pages: 074-098

10.3934/genet.2016.1.74 Get It

AbstractThe cranial neural crest and the cranial mesoderm are the source of tissues from which the bone and cartilage of the skull, face and jaws are constructed. The development of the cranial mesoderm is not well studied, which is inconsistent with its importance in craniofacial morphogenesis as a source of precursor tissue of the chondrocranium, muscles, vasculature and connective tissues, mechanical support for tissue morphogenesis, and the signaling activity that mediate interactions with the cranial neural crest. Phenotypic analysis of conditional knockout mouse mutants, complemented by the transcriptome analysis of differentially enriched genes in the cranial mesoderm and cranial neural crest, have identified signaling pathways that may mediate cross-talk between the two tissues. In the cranial mesenchyme, Bmp4 is expressed in the mesoderm cells while its signaling activity could impact on both the mesoderm and the neural crest cells. In contrast, Fgf8 is predominantly expressed in the cranial neural crest cells and it influences skeletal development and myogenesis in the cranial mesoderm. WNT signaling, which emanates from the cranial neural crest cells, interacts with BMP and FGF signaling in monitoring the switch between tissue progenitor expansion and differentiation. The transcription factor Twist1, a critical molecular regulator of many aspects of craniofacial development, coordinates the activity of the above pathways in cranial mesoderm and cranial neural crest tissue compartments.
Preeclampsia/Eclampsia candidate genes show altered methylation in maternal leukocytes of preeclamptic women at the time of delivery
Sun, Zhifu , Borowski, Kristi, Davies, Norman, Rose, Carl H., White, Wendy M, Borowski, Kristi S, Brost, Brian C, Davies, Norman P, Garovic, Vesna D. , White, Wendy , Brost, Brian , Sun, Zhifu

Mayo Clinic

Hypertension in Pregnancy | April 11, 2016 | Volume: 35 | Issue: 3 | Pages: 394-404

10.3109/10641955.2016.1162315 | PMID 27064514 Get It

Cortical phosphorylated α‐Synuclein levels correlate with brain wave spectra in Parkinson's disease
Caviness, John N., Lue, Lih‐Fen , Hentz, Joseph G. , Schmitz, Christopher T., Shill, Holly A. , Beach, Thomas G. , Walker, Douglas G. , Adler, Charles H. , Sabbagh, Marwan Noel , Schmitz, Christopher

Mayo Clinic

Movement Disorders | April 10, 2016 | Volume: 31 | Issue: 7 | Pages: 1012-1019

10.1002/mds.26621 | PMID 27062301 Get It

ABSTRACTIntroductionQuantitative EEG features have been identified as surrogates and predictors of cognitive decline/dementia, a common feature of progressive PD. The biochemical correlates for altered quantitative EEG features are unknown. Our primary objective was to test the hypothesis that quantitative EEG measures correlate with cortical levels of phosphorylated α‐synuclein, a modified form of the synaptic protein α‐synuclein, in PD cases, in contrast to other pathology‐associated proteins. A secondary objective was to explore the same correlations among cellular fractions of these proteins.MethodsWe used posterior cingulate cortex autopsy tissue from 44 PD subjects with various degrees of cognitive decline, who had undergone EEG. In this brain region, which is a major hub of the default mode network, biochemical measurements for levels of phosphorylated α‐synuclein, unmodified α‐synuclein, amyloid beta peptide, phosphorylated tau, and key synaptic proteins were analyzed and data correlated with spectral EEG measures.ResultsFindings revealed significant correlations between background rhythm peak frequency and all bandpower values (highest in delta bandpower) with total phosphorylated α‐synuclein, but not any correlation with total α‐synuclein, phosphorylated tau protein, amyloid beta peptide, or synaptic proteins. Certain fractions of synaptosomal‐associated protein 25 showed correlation with some quantitative EEG measures.ConclusionsThese data show an association between increased phosphorylation of α‐synuclein and the abnormal EEG signatures of cognitive decline. Results suggest that quantitative EEG may provide an in vivo approximation of phosphorylated α‐synuclein in PD cortex. This adds to previous evidence that quantitative EEG measures can be considered valid biomarkers of PD cognitive decline. © 2016 International Parkinson and Movement Disorder Society
Prevalence of Submandibular Gland Synucleinopathy in Parkinson’s Disease, Dementia with Lewy Bodies and other Lewy Body Disorders
Beach, Thomas G. , Sue, Lucia I., Walker, Douglas G. , Dugger, Brittany N. , Shill, Holly A. , Driver‐Dunckley, Erika , Caviness, John N., Intorcia, Anthony J., Filon, Jessica, Scott, Sarah, Garcia, Angelica, Hoffman, Brittany, Belden, Christine M. , Davis, Kathryn, Driver-Dunckley, Erika, Adler, Charles H. , Serrano, Geidy E. , Sabbagh, Marwan Noel , Dugger, Brittany N

Mayo Clinic

Journal of Parkinson’s Disease | April 6, 2016 | Volume: 6 | Issue: 1 | Pages: 153-163

10.3233/jpd-150680 | PMID 26756744 Get It

Background: Clinical misdiagnosis, particularly at early disease stages, is a roadblock to finding new therapies for Lewy body disorders. Biopsy of a peripheral site might provide improved diagnostic accuracy. Previously, we reported, from both autopsy and needle biopsy, a high prevalence of submandibular gland synucleinopathy in Parkinson’s disease (PD). Here, we report on an extension of these studies to subjects with dementia with Lewy bodies (DLB) and other Lewy body disorders in 228 autopsied subjects from the Arizona Study of Aging and Neurodegenerative Disorders. Objective: To provide an estimate of the prevalence of histological synucleinopathy in the submandibular glands of subjects with PD and other Lewy body disorders. Methods: Submandibular gland sections from autopsied subjects were stained with an immunohistochemical method for α-synuclein phosphorylated at serine 129. Included were 146 cases with CNS Lewy-type synucleinopathy (LTS), composed of 46 PD, 28 DLB, 14 incidental Lewy body disease (ILBD), 33 Alzheimer’s disease with Lewy bodies (ADLB) and 2 with progressive supranuclear palsy and Lewy bodies (PSPLB). Control subjects included 79 normal elderly, 15 AD, 12 PSP, 2 conticobasal degeneration (CBD) and 2 multiple system atrophy (MSA). Results: Submandibular gland LTS was found in 42/47 (89%) of the PD subjects, 20/28 (71%) DLB, 4/33 (12%) ADLB and 1/9 (11%) ILBD subjects but none of the 110 control subjects. Conclusions: These results provide support for further clinical trials of in vivo submandibular gland diagnostic biopsy for PD and DLB. An accurate peripheral biopsy diagnosis would assist subject selection for clinical trials and could also be used to verify other biomarkers.
Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome
Shaffer, Brian C. , Ahn, Kwang Woo , Hu, Zhen‐Huan , Malone, Adriana K. , Valcárcel, David , Hamilton, Betty K. , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Warlick, Erica D. , Wirk, Baldeep , Sabloff, Mitchell , Fasan, Omotayo , Gerds, Aaron T. , Marks, David I. , Olsson, Richard F. , Wood, William A. , Costa, Luciano J. , Miller, Alan M. , Cortes, Jörge E. , Daly, Andrew , Kindwall‐Keller, Tamila L. , Kamble, Rammurti T., Rizzieri, David A. , Cahn, Jean‐Yves , William, Basem M. , Litzow, Mark R. , Wiernik, Peter H. , Vij, Ravi , Üstün, Celalettin , Copelan, Edward A. , Kalaycio, Matt, Alyea, Edwin P. , Sobecks, R., Pavletic, Steven Z. , Tallman, Martin S. , Saber, Wael , Nishihori, Taiga , Bacher, Ulrike , Hamilton, Betty, Kharfan-Dabaja, Mohamed A., Cutler, Corey, Warlick, Erica, Wirk, Baldeep Mona, Marks, David, Olsson, Richard, Wood, William Allen, Cortes, Jorge, Kindwall-Keller, Tamila L, Kamble, Rammurti, William, Basem, Savani, Bipin N. , Copelan, Edward, Popat, Uday, Maziarz, Richard, Alyea, Edwin, Sobecks, Ron, Pavletic, Steven, Tallman, Martin, Grunwald, Michael R. , Cutler, Corey S. , Reshef, Ran , Gale, Robert Peter , Liesveld, Jane L. , Popat, Uday R , Maziarz, Richard Thomas , Gerds, Aaron T , Saad, Ayman , Olsson, Richard F , Cortes, Jorge , William, Basem , Costa, Luciano J , Sabloff, Mitchell , Wood, William A , Valcárcel, David

Mayo Clinic

Journal of Clinical Oncology | April 5, 2016 | Volume: 34 | Issue: 16 | Pages: 1864-1871

10.1200/jco.2015.65.0515 | PMID 27044940 Get It

Purpose To develop a system prognostic of outcome in those undergoing allogeneic hematopoietic cell transplantation (allo HCT) for myelodysplastic syndrome (MDS). Patients and Methods We examined 2,133 patients with MDS undergoing HLA-matched (n = 1,728) or -mismatched (n = 405) allo HCT from 2000 to 2012. We used a Cox multivariable model to identify factors prognostic of mortality in a training subset (n = 1,151) of the HLA-matched cohort. A weighted score using these factors was assigned to the remaining patients undergoing HLA-matched allo HCT (validation cohort; n = 577) as well as to patients undergoing HLA-mismatched allo HCT. Results Blood blasts greater than 3% (hazard ratio [HR], 1.41; 95% CI, 1.08 to 1.85), platelets 50 × 109/L or less at transplantation (HR, 1.37; 95% CI, 1.18 to 1.61), Karnofsky performance status less than 90% (HR, 1.25; 95% CI, 1.06 to 1.28), comprehensive cytogenetic risk score of poor or very poor (HR, 1.43; 95% CI, 1.14 to 1.80), and age 30 to 49 years (HR, 1.60; 95% CI, 1.09 to 2.35) were associated with increased hazard of death and assigned 1 point in the scoring system. Monosomal karyotype (HR, 2.01; 95% CI, 1.65 to 2.45) and age 50 years or older (HR, 1.93; 95% CI, 1.36 to 2.83) were assigned 2 points. The 3-year overall survival after transplantation in patients with low (0 to 1 points), intermediate (2 to 3), high (4 to 5) and very high (≥ 6) scores was 71% (95% CI, 58% to 85%), 49% (95% CI, 42% to 56%), 41% (95% CI, 31% to 51%), and 25% (95% CI, 4% to 46%), respectively (P < .001). Increasing score was predictive of increased relapse (P < .001) and treatment-related mortality (P < .001) in the HLA-matched set and relapse (P < .001) in the HLA-mismatched cohort. Conclusion The proposed system is prognostic of outcome in patients undergoing HLA-matched and -mismatched allo HCT for MDS.
X Chromosome Abnormal Inactivation: A unique Factor for Women’s Diseases?
Wu, Cuijiao, Sun, Zhifu , Sun, Zhifu

Mayo Clinic

Epigenomics | April 1, 2016 | Volume: 8 | Issue: 4 | Pages: 447-450

10.2217/epi.16.2 | PMID 27032507 Get It

Linkage and related analyses of Barrett's esophagus and its associated adenocarcinomas
Sun, Xiangqing , Elston, Robert C. , Faulx, Ashley L., Shaheen, Nicholas J. , Wang, Jean S. , Iyer, Prasad G. , Guda, Kishore , Markowitz, Sanford D. , Barnholtz‐Sloan, Jill S. , Chandar, Apoorva K., Brock, Wendy , Chak, Amitabh , Falk, Gary W. , Grady, William M. , Mittal, Sumeet K. , Canto, Marcia Irene , Abrams, Julian A , Willis, Joseph , Barnholtz-Sloan, Jill S

Mayo Clinic

Molecular Genetics & Genomic Medicine | March 19, 2016 | Volume: 4 | Issue: 4 | Pages: 407-419

10.1002/mgg3.211 | PMID 27468417 Get It

AbstractBackgroundFamilial aggregation and segregation analysis studies have provided evidence of a genetic basis for esophageal adenocarcinoma (EAC) and its premalignant precursor, Barrett's esophagus (BE). We aim to demonstrate the utility of linkage analysis to identify the genomic regions that might contain the genetic variants that predispose individuals to this complex trait (BE and EAC).MethodsWe genotyped 144 individuals in 42 multiplex pedigrees chosen from 1000 singly ascertained BE/EAC pedigrees, and performed both model‐based and model‐free linkage analyses, using S.A.G.E. and other software. Segregation models were fitted, from the data on both the 42 pedigrees and the 1000 pedigrees, to determine parameters for performing model‐based linkage analysis. Model‐based and model‐free linkage analyses were conducted in two sets of pedigrees: the 42 pedigrees and a subset of 18 pedigrees with female affected members that are expected to be more genetically homogeneous. Genome‐wide associations were also tested in these families.ResultsLinkage analyses on the 42 pedigrees identified several regions consistently suggestive of linkage by different linkage analysis methods on chromosomes 2q31, 12q23, and 4p14. A linkage on 15q26 is the only consistent linkage region identified in the 18 female‐affected pedigrees, in which the linkage signal is higher than in the 42 pedigrees. Other tentative linkage signals are also reported.ConclusionOur linkage study of BE/EAC pedigrees identified linkage regions on chromosomes 2, 4, 12, and 15, with some reported associations located within our linkage peaks. Our linkage results can help prioritize association tests to delineate the genetic determinants underlying susceptibility to BE and EAC.
Emodin via colonic irrigation modulates gut microbiota and reduces uremic toxins in rats with chronic kidney disease
Zeng, Yuqun , Lu, Fuhua , Lu, Zhaoyu , Liu, Xusheng , Cha, Chen , Qu, Pinghua , Li, Dingcheng , Qu, Yan-Ni , Zou, Chuan , Dai, Zhenhua , Hua, Zheng‐Shuang

Mayo Clinic

Oncotarget | March 18, 2016 | Volume: 7 | Issue: 14 | Pages: 17468-17478

10.18632/oncotarget.8160 | PMID 27003359 Get It

Predicting Barrett's Esophagus in Families: An Esophagus Translational Research Network (BETRNet) Model Fitting Clinical Data to a Familial Paradigm
Sun, Xiangqing , Elston, Robert C. , Barnholtz‐Sloan, Jill S. , Faulx, Ashley L., Mittal, Sumeet K. , Shaheen, Nicholas J. , Wang, Jean S. , Iyer, Prasad G. , Tian, Ye D. , Willis, Joseph , Guda, Kishore , Markowitz, Sanford D. , Chandar, Apoorva K., Warfe, James M. , Brock, Wendy , Chak, Amitabh , Falk, Gary W. , Grady, William M. , Canto, Marcia Irene , Abrams, Julian A , Willis, Joseph E , Barnholtz-Sloan, Jill S

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | February 29, 2016 | Volume: 25 | Issue: 5 | Pages: 727-735

10.1158/1055-9965.epi-15-0832 | PMID 26929243 Get It

Abstract Background: Barrett's esophagus is often asymptomatic and only a small portion of Barrett's esophagus patients are currently diagnosed and under surveillance. Therefore, it is important to develop risk prediction models to identify high-risk individuals with Barrett's esophagus. Familial aggregation of Barrett's esophagus and esophageal adenocarcinoma, and the increased risk of esophageal adenocarcinoma for individuals with a family history, raise the necessity of including genetic factors in the prediction model. Methods to determine risk prediction models using both risk covariates and ascertained family data are not well developed. Methods: We developed a Barrett's Esophagus Translational Research Network (BETRNet) risk prediction model from 787 singly ascertained Barrett's esophagus pedigrees and 92 multiplex Barrett's esophagus pedigrees, fitting a multivariate logistic model that incorporates family history and clinical risk factors. The eight risk factors, age, sex, education level, parental status, smoking, heartburn frequency, regurgitation frequency, and use of acid suppressant, were included in the model. The prediction accuracy was evaluated on the training dataset and an independent validation dataset of 643 multiplex Barrett's esophagus pedigrees. Results: Our results indicate family information helps to predict Barrett's esophagus risk, and predicting in families improves both prediction calibration and discrimination accuracy. Conclusions: Our model can predict Barrett's esophagus risk for anyone with family members known to have, or not have, had Barrett's esophagus. It can predict risk for unrelated individuals without knowing any relatives' information. Impact: Our prediction model will shed light on effectively identifying high-risk individuals for Barrett's esophagus screening and surveillance, consequently allowing intervention at an early stage, and reducing mortality from esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev; 25(5); 727–35. ©2016 AACR.
Peripheral Synucleinopathy in Early Parkinson's Disease: Submandibular Gland Needle Biopsy Findings
Dugger, Brittany N. , Hentz, Joseph G. , Hinni, Michael L., Driver‐Dunckley, Erika , Mehta, Shyamal, Sue, Lucia I., Duffy, Amy, Intorcia, Anthony J., Filon, Jessica, Pullen, Joel, Walker, Douglas G. , Beach, Thomas G. , Driver-Dunckley, Erika, Adler, Charles H. , Lott, David G. , Mehta, Shyamal H. , Serrano, Geidy E. , Dugger, Brittany N

Mayo Clinic

Movement Disorders | January 22, 2016 | Volume: 31 | Issue: 2 | Pages: 250-256

10.1002/mds.26476 | PMID 26799362 Get It

ABSTRACTIntroductionFinding a peripheral tissue biopsy site to diagnose early PD would be of value for clinical care, biomarker validation, and as research enrollment criteria. Whereas autopsy and advanced PD studies suggest that the submandibular gland is an important biopsy site, there are no studies in early PD. The aim of this study was to determine whether needle biopsy of the submandibular gland reveals Lewy type alpha‐synucleinopathy in early PD.MethodsTwenty‐five early PD (duration < 5 years) and 10 controls underwent transcutaneous needle core biopsies of the submandibular gland. Tissue was stained for phosphorylated alpha‐synuclein, reviewed blind to clinical diagnosis, and only nerve element staining was considered positive.ResultsMean (standard deviation) age was 69.5 (8.3) for the PD group, 64.8 (8.0) years for controls, and disease duration 2.6 (1.1) years. Six PD and 1 control subject had inadequate glandular tissue. Positive staining was found in 14 of 19 (74%) PD and 2 of 9 (22%) control subjects. PD‐positive and ‐negative cases did not differ clinically. Adverse events (mainly swelling and bruising) were common (77% of cases), but were minor and transient.ConclusionsSubmandibular gland needle biopsies identified phosphorylated alpha‐synuclein staining in 74% of early PD subjects. False positives may be true false positives or may represent prodromal PD. If confirmed in larger studies with eventual autopsy confirmation, the potential value of submandibular gland biopsies for early PD may be to aid in clinical trial inclusion/exclusion and eventually serve as a gold standard for biomarker studies short of autopsy confirmation. © 2016 International Parkinson and Movement Disorder Society